http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
GSK Luncheon Symposium : New Insight of Cervical Cancer Prevention from Japan Experience
( Kon No Ryo ) 대한산부인과학회 2012 대한산부인과학회 학술대회 Vol.98 No.-
HPV vaccination is one of the most useful strategies to reduce cervical cancer. In Japan, routine vaccination is free, individual (clinic based) and funded by regional governments. On the other hand, non-routine vaccines are basically self-pay. Clinical research on HPV vaccines targeted at Japanese women started in 2007. In November, 2008, we established the Japanese Expert Board for the Eradication of Cervical Cancer with goal of obtaining national funding for HPV vaccination as a routine vaccine and high coverage of more accurate screening. Members of the Project include Drs, Nurses, Midwives, Cancer survivors, and Cancer Association. We presented the recommendation with evidence showing the advantages and cost effectiveness for governmental funding. To educate and raise awareness in politicians, policy makers, health professionals, mass media and the general public, many educational campaigns, seminars and promotions were also implemented. Cervarix was licensed and became available first as a private (non routine) vaccine from December, 2009. Since regional governments funding HPV vaccination with their own budget gradually increased, the national government judged the establishment of a specific fund for HPV vaccine targeted at girls aged 13 to 16 to be necessary. Consequently, the national government and regional governments provide a tentative budget half and half and an interim nationwide HPV vaccination program was started since November, 2010. Uptake ratio was estimated by MHLW at 70% (1st dose, March, 2012) of the target age groups. In May, 2012, Ministry of Health, Labour and Welfare approved HPV vaccination as one of the national routine immunisation program.